Tumor-specific major histocompatibility-II expression predicts benefit to anti⇓PD-1/L1 therapy in patients with HER2-negative primary breast cancer

Paula I. Gonzalez-Ericsson, Julia D. Wulfkhule, Rosa I. Gallagher, Xiaopeng Sun, Margaret L. Axelrod, Quanhu Sheng, Na Luo, Henry Gomez, Violeta Sanchez, Melinda Sanders, Lajos Pusztai, Emanuel Petricoin, Kim R.M. Blenman*, Justin M. Balko*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Fingerprint

Dive into the research topics of 'Tumor-specific major histocompatibility-II expression predicts benefit to anti⇓PD-1/L1 therapy in patients with HER2-negative primary breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences